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Qualityoflife has become increasingly moreimportant formen diagnosed with prostate cancer. In lightof this andthe recognized
risks of androgen deprivation therapy (ADT), the guidelines and use of ADT have changed signiﬁcantly over the last few years.
This paper reviews the current recommendations and the future perspectives regarding ADT. The beneﬁts of ADT are evident
neoadjuvantly and adjuvantly in patients treated with external beam radiation therapy for intermediate- and high-risk disease, in
patients who have undergone prostatectomy with lymph node involvement, in high-risk patients after deﬁnitive therapy, and in
patients who have developed progression or metastasis. Finally, this paper reviews the risks and beneﬁts of each of these scenarios
and the risks of androgen deprivation in general, and it delineates the areas where ADT was previously recommended, but where
evidence is lacking for its additional beneﬁt.
1.Introduction
Prostate cancer is the most frequently diagnosed cancer
in males in the United States and has long been asso-
ciated with hormone dependence [1]. The use of andro-
gen deprivation therapy (ADT) for men with advanced
prostate cancer continues to be the recommended therapy.
Androgen deprivation is deﬁned as a lowering of serum
testosterone through the administration of a luteinizing
hormone releasing hormone (LHRH) agonist. However, it
has become increasingly apparent that ADT is not without
its own risks. ADT-associated risks continue to become
more fully elucidated through multiple recently published
retrospective and prospective studies. These risks are no
longer solely deﬁned by life span and cancer progression
but also by how ADT aﬀects quality of life based on a
patient’s physical, ﬁnancial, and emotional well being. There
is also evidence that a “middle of the road”, intermittent
androgen deprivation therapy (IADT) may soon be appro-
priate care for some individuals with prostate cancer. This
paper examines IADT and the clinical studies that are being
done that suggest it as a possible alternative in the future.
This paper also reviews the ﬁndings of investigations into
the risks and beneﬁts of ADT. It will delineate areas where
ADT use has been deemed inappropriate/ineﬀective and
summarizes the current clinical situations where ADT use
remains recommended.
2.AndrogenDeprivationandAssociated
Adverse Events
2.1. Cardiovascular Disease. ADTutilizes the fact that malig-
nant prostate cells require androgen stimulation for growth
and division. ADT attempts to deny malignant cells a
growth stimulus, potentially resulting in a slowing of cancer
growth and progression. However, androgen receptors are
not located only within the prostrate. Androgen receptors
are known to be expressed in endothelial cells and have
been shown to regulate a number of endothelial responses
[2]. ADT has been shown to lead to an increase in
cardiovascular disease that correlates with an increase in
myocardial infarction and even sudden cardiac death in
some studies. Keating et al. found that men with prostate
cancer using a GnRH agonist were associated with an
increased risk of coronary heart disease (adjusted hazard2 Prostate Cancer
ratio (HR), 1.16; 95% conﬁdence interval (CI), 1.10 to
1.21), myocardial infarction (adjusted HR, 1.11; 95% CI,
1.01 to 1.21), and sudden cardiac death or life-threatening
ventricular arrhythmia (adjusted HR, 1.16; 95% CI, 1.05
to 1.27). This increased risk of coronary heart disease was
evident in as few as one to four months [3]. It is now well
understood that the decreased lean body mass and increased
body fat composition seen grossly with the administration
of ADT [4] are also correlated with negative changes in the
serum lipid proﬁle, an increased risk of insulin resistance
and an increased risk of coronary artery disease. A twelve-
month study of 40 men with prostate cancer demonstrated
thatADTincreased serumtotalcholesterolby9percent,low-
density lipoprotein cholesterol by 7 percent and triglycerides
by 27 percent [5]. This risk of the development of diabetes
and coronary artery disease has been conﬁrmed in other
studies and appears to be even greater in men over 65 years
of age [6]. In a 3-month prospective study of nondiabetic
men, ADT signiﬁcantly increased fasting plasma insulin by
26 percent and decreased insulin sensitivity by 13 percent
[7]. Description of this “metabolic syndrome” and the
concern about its impact on survival on patients treated
with ADT led to the reanalysis of the RTOG 92-02 trial. In
this trial, 1554 men with locally advanced prostate cancer
were treated with neoadjuvant goserelin for 4 months prior
to radiation therapy and either no additional therapy or
for 24 additional months. Although a striking increase in
death from coronary artery disease was not seen in the
men who underwent prolonged treatment with ADT, the
authors did note that “although there was a signiﬁcant
advantage for all prostate cancer-speciﬁc endpoints (with
prolonged therapy), the longer-term arm of ADT in RTOG
92-02 was associated with greater noncancer mortality
than [the] short-term [arm].” They go on to state that
“compared to the general population, men with prostate
cancer (are known to) have higher rates of noncancer death
and GnRH agonists may contribute to this through multiple
mechanisms” [8]. An interim analysis of a recent prospective
randomized trial showed a reversal of the negative eﬀects on
low density lipoprotein (LDL), very low density lipoprotein
(VLDL), and high density lipoprotein (HDL) with the
administration of toremifene [9]; a similar eﬀect would
likely be seen with 3-hydroxy-3-methylglutarylcoenzyme A
reductase inhibitors or “statins.” It is recommended at this
time to screen carefully and treat all patients on ADT
for hyperlipidemia, diabetes, and coronary artery disease
[10].
2.2. Skeletal Disease. Men undergoing ADT have an in-
creased risk of developing osteoporosis due to androgen
deprivation. Osteoporosis onset is early and associated with
a decrease in bone mineral density leading to an increase risk
of bone fracture [11]. Several studies and research have been
underwaytoinvestigatethebesttreatmentatbothpreventing
and treating ADT-associated fractures. It is recommended
thatall men over50, and particularly those treated with ADT
be supplemented with 800 to 1000IU of vitamin D, 1200mg
of calcium daily, frequent weight-bearing exercise, and to
be screened for osteoporosis regularly [12]. Those at higher
risk for fracture should be treated with bisphosphonates.
A prospective randomized study of alendronate (70mg
weekly by mouth versus placebo) started at the initiation
of ADT showed improvement of spine and hip densities,
and this ﬁnding was less signiﬁcant it was initiated after
just one year of ADT [13]. Recent studies have supported
ﬁndings that 60mg denosumab, a monoclonal antibody to
RANKL, twice yearly helps prevent and treat ADT-induced
bone loss and fractures [14]. Quarterly or annual 4mg
zoledronic acid infusions for men with normal creatinine
show similar or even greater beneﬁts, although the rare
risk of osteonecrosis can be devastating [13, 15, 16]. It is
the recommendation of the National Comprehensive Cancer
Network that zoledronic acid be administered to men with
bony progressive metastatic prostate cancer on ADT to help
prevent skeletal related events.
2.3. Quality of Life: Cognition and Physical Function. Cog-
nition and physical function are important factors for how
a patient deﬁnes quality of life, and there is increasing
evidence that ADT may have adverse eﬀects on these
functions as well. A retrospective trial showed that up to
27% of patients on ADT suﬀered a diagnosable psychiatric
illness during their treatment, and that, in patients on ADT
tested over time, many lost cognition in one, if not two,
measurable areas [17, 18]. However, ADT directly resulting
in permanent cognitive dysfunction remains controversial.
A recent prospective controlled study found no consistent
evidence that after one year of ADT use there is declining
cognitive function [19].Additional studiessuggestthat while
there may be some cognitive dysfunction with ADT use,
cognition may return to baseline with cessation [20]. A
recent prospective controlled study of men on androgen
deprivation more than 6 months found a decline of lower
body physical function with a statistically slower walk
and chair-rise times with treatment [21]. A retrospective
study from the Mayo Clinic in Scottsdale found that the
average hemoglobin drop on patients treated with LHRH
antagonists is 1.6g/dL, which may contribute to the physical
decline seen in these patients [22]. Additional studies have
documented decreases in hemoglobin concentration, Smith
et al. noted that eighteen of 22 (82%) men with baseline
hemoglobin concentrations 13.5g/dl or greater developed
anemia during ADT [5]. As previous studies have found a
profound and prolonged suppression of testosterone long
after the cessation of LHRH analogues (53% of men who
had been on ADT for 4 or more years remain castrate for
up to 2.5 years) [23], there is concern that the adverse
risks of coronary artery disease, diabetes, osteoporosis,
cognitive/physical changes, and anemia could persist beyond
active therapy resulting in long-term impacts on quality
of life. Identifying the risks of ADT is important because
individuals with prostate cancershould be made aware ofthe
eﬀectsof treatment on their qualityof life [24]. These factors
shouldbeassessed duringthedecision-makingprocessabout
desired treatment.Prostate Cancer 3
3. IntermittentADT
Although it would seem that the ﬁnancial costs of ADT are
minimal, a recent study showed, if used for a signiﬁcant
amount of time, the cost of ADT would quickly be greater
than that of radical prostatectomy or external beam therapy
[25]. At a time when the cost to the government to cover
medical costs for its citizens is rapidly approaching one-
half of the United States budget, this is not a trivial issue.
IADT would seem to be a “middle of the road” option
oﬀering the ability to deliver the proven eﬃcacy of constant
ADT while lowering the adverse events and cost. A recent
European study found no signiﬁcant diﬀerence in survival
between intermittent ADT compared to continuous ADT.
The study found that the greater number of cancer deaths
in the intermittent arm (106 verses 84) were balanced
by the greater number of cardiovascular deaths in the
continuousarm(52verses41)[26].AlargeongoingphaseIII
trial by Southwest Oncology Group (SWOG) 9346 involves
1500 patients with stage D2 prostate cancer. Subjects were
pretreated to a PSA of =5ng/mL and underwent a 7-
month induction period with goserelin and bicalutamide.
Subjects with a stable or declining PSA level of =4ng/mL
were randomized to continuous ADT or IADT. Patients in
the IADT group remained oﬀ treatment until PSA began
to rise above their baseline levels, >20ng/mL, or above
a point determined by the investigator’s discretion. These
cycles continued until clinical or PSA progressing appeared
[27]. Results are still pending but could demonstrate the
long-term utility of IADT. An article update on IADT
stated that, “Although evidence suggests that IADT performs
a tl e a s ta sw e l la sc o n t i n u o u sA D Ti nt e r m so fs u r v i v a l
and perhaps better in terms of side eﬀects IADT still
remains experimental and unproven regarding long term
implications of disease progression and survival impact.”
[28] Studies to date demonstrate that IADT appears to
be a suitable alternative to constant ADT with associated
d e c r e a s e dc o s t sa n di m p r o v e dp a t i e n tq u a l i t yo fl i f e .A
prospective phase II study found that patients receiving
IADT reported beneﬁts in the oﬀ-treatment interval with a
reported increase in quality of life [29]. Further randomized
studies will also be required to assess the long-term cardio-
vascular, skeletal, and cognitive eﬀects of IADT compared to
constant ADT.
Undoubtedly, the adverse risks associated with ADT are
justiﬁed in a speciﬁc subset ofprostate cancerpatients. How-
ever, with the increased awareness about ADT-associated
risks coupled with ADT’s questionable eﬃcacy, there has
beenashift intherecommendationofADTinseveralclinical
scenarios outlined below.
3.1. ADT Is Likely Unwarranted with
Low-Risk Localized Disease
3.1.1. Preprostatectomy or Postprostatectomy. Recommenda-
tions for neoadjuvant androgen deprivation prior to or after
prostatectomy have waned in men with localized disease.
Many studies have been completed evaluating ADT eﬃcacy
in this cohort and have demonstrated a possible decrease
in positive surgical margins; however, there has been no
documented improvement in overall survival, making it
diﬃcult to justify the risks of ADT [30]. One of the
largest prospective randomized prostate cancer trials, the
Early Prostate Cancer (EPC) trial, evaluated 150mg of
bicalutamide daily in addition to standard therapy for men
with low- and high-risk disease. Analysis of the overall trial
did not show any advantage for its use in low-risk patients
treated with surgery, radiation, or observation. Although, in
general, antiandrogen monotherapy is thought to be inferior
and less well tolerated than traditional androgen deprivation
[31], the study did suggest some beneﬁt in higher-risk
patients with locally advanced or micrometastatic disease in
progression-free survival, but no beneﬁt in overall survival
was observed [32].
3.1.2. Prior to External Beam Radiation/Brachytherapy.
Although earlier studies might have suggested some beneﬁt
for neoadjuvant ADT prior to external beam radiation for
patients with localized disease, with higher dosing [33],
conformal techniques that appear to make doses of 70 to
79Gy possible with minimal toxicity [34], and the wider
availability of brachytherapy, it appears that, in general,
neoadjuvant androgen deprivation is no longer recom-
mended prior to radiation therapy for patients with low-risk
prostate cancer [35, 36].
3.1.3. No Primary Treatment. Results of a large retrospective
trial recently published in JAMA evaluated 19,271 with
localized prostate cancer found no increase in 10-year overall
survival inmentreated withandrogendeprivationcompared
to conservative management; notably, there was a lower 10-
year prostate-cancer-speciﬁc survival in men treated with
primary androgen deprivation [37]. Similarly, when Dr.
Studer reported on the results of the EORTC trial wherein
939 men with prostate cancer not suitable for local curative
treatment wereevaluatedaftertheirrandomizationtoimme-
diateversusdeferredADT,heconcludedthat“patientswith a
baseline PSA>50ng/mL and/or a PSADT (prostate-speciﬁc
antigen doubling time) <12 months were at increased risk
to die from prostate cancer and might have beneﬁted
from immediate ADT whereas patients with a baseline
PSA<50ng/mL and a slow PSADT(>12months) were likely
to die of causes unrelated to prostate cancer, and thus could
be spared the burden of immediate ADT” [38]. The group
of men with low-risk tumors who do not get treated with
ADTmay beneﬁtfrom active surveillance where similar rates
of eﬃcacy are achieved with decreased morbidity compared
to deﬁnitive therapy or androgen deprivation [39, 40]. Large
trialshavesuggestedthatthereislittlebeneﬁtinscreeningfor
prostate cancer (or at least a large number needed to treat to
see beneﬁt), particularly for men over 70. This same cohort
that previously would have been treated with ADT due to
inability to tolerate deﬁnitive therapy may now be likely to
avoidscreening,diagnosis, andovertreatment withandrogen
deprivation as well [41, 42].4 Prostate Cancer
3.2. ADT Is Warranted with Advanced Disease
3.2.1. Advanced Disease; PSA>50, PSADT<12 Months.
Clearly the risks associated with ADT are worth the possible
beneﬁt in men with high-stage, high-grade tumors, with
rapid recurrence after therapy, doubling times under 12
months and/or total PSA values greater than 50ng/mL [38].
These men should also have consultation with medical
oncology early and should be considered strongly for clinical
trials.
3.2.2. Advanced Disease Prior to External Beam Radiation.
The administration of neoadjuvant ADT remains an inde-
pendent predictor of long-term control in patients with
intermediateandhigh-riskcancertreatedwithexternalbeam
radiation (EBXRT)and should be given prior to therapy [43,
44]. A randomized trial of 802 Australian men found that
3 months of neoadjuvant ADT showed an inferior prostate-
cancer-speciﬁc mortality to men treated with 6 months with
locally advanced prostate cancer, so a treatment with 4 to
6 months of neoadjuvant ADT is recommended prior to
external beam radiation [45]. The initial ﬁnding in the
randomized controlledRTOG/EORTCtrials showing thatan
additional 24 to 36 months of ADT after EBXRT improves
survival in men with high-risk disease and is recommended
aswell[46,47].Inthesetrials,androgendeprivationhasbeen
achieved using an LHRH agonist as well as an antiandrogen.
Similar eﬃcacy may be able to be achieved with LHRH
monotherapy, but formal comparative studies have not been
performed. Interestingly, when a group in Spain looked at
predictors for hematuria in patients who had undergone
conformal prostate radiation for cancer, the administration
of adjuvant androgen deprivation was protective (a factor of
5) for the development of hematuria (whereas transurethral
resection [TURP] increased the risk three times) [48].
3.2.3. Lymph Node Involvement at Prostatectomy. There is
support for immediate ADT in men found to have lymph
node involvement at prostatectomy. Only one random-
ized, controlled study has been performed to investigate
this situation to date. Although this trial is small and
may have exaggerated survival advantages by delaying the
initiation of ADT in the initially untreated group, the
study showed a signiﬁcant improvement in overall, disease-
speciﬁc, and progression-free survival advantage for patients
who undergo early ADT in this setting [49].
3.2.4. Local Obstructive Symptoms/Metastatic Disease. Data
from the MRC trial published in 1997 showing that ADT
helps decrease symptoms from patients with advanced
disease is still to be considered today. This prospective
randomized trial of 938 men with locally advanced or
asymptomatic metastatic prostate cancer showed that rates
of pathological fracture, spinal cord compression, ureteric
obstruction, the development of extraskeletal metastases
(and pain from these metastases) as well as death from
prostate cancer are statistically more common in men who
were not treated with early androgen deprivation [50].
It is important to note that since the introduction of
PSA screening there has been a signiﬁcant stage migration
downward, so patients with this level of disease burden may
be less common.
4.AdjuvantlyinCryotherapy
In men wishing to undergo primary cryotherapy for prostate
cancer, the largest series in the literature reports that ADT
used adjuvantly can be successful and may be beneﬁcial
with this treatment modality [51]. Recent studies have also
suggested that cryotherapy is becoming a safe and feasible
treatment for prostate cancer. However, as previously dis-
cussed, quality of life after a patient undergoes cryotherapy
is important and further multi-institutional studies will
be necessary to adequately assess the most appropriate
therapy for the patient [52]. Additional studies comparing
cryotherapy alone to cryotherapy with ADT will also need
to be completed as cryotherapy treatment for prostate cancer
advances.
4.1. Further Risk Stratiﬁcation Is Warranted
4.1.1. Biochemical Recurrence after Therapy. Data following
the natural course of men with recurrence after primary
therapy show that very few die of their disease and that fre-
quentlycompeting causes ofdeathand from prostate cancer-
speciﬁc death are equally likely upon recurrence of disease
[53]. A literature review published in JAMA concluded
that “although patients with increasing prostate-speciﬁc
antigenlevelsafterlocaltreatment withoutmetastaticdisease
frequently undergo ADT, the beneﬁts of this strategy are not
clear...and need to be weighed carefully against substantial
risks and adverse eﬀects on quality of life” [54]. This litera-
ture review, while indicating the need for additional studies,
suggests the usefulness of a risk-stratiﬁed approach. This
approach includes the incorporation of known risk factors
for recurrent aggressive disease to deﬁne which patients need
more aggressive early therapy and which patients may be
able to be spared the adverse events of androgen deprivation
at the detection of biochemical recurrence. The elements
of risk stratiﬁcation may include pretreatment PSA, PSA
velocity, Gleason score, volume of tumor or stage [55–57],
PSA velocity or total value [38, 58], PSA nadir and time to
recurrenceaftertherapy[59,60],andpossiblythepresenceof
circulating tumor cells [61], as all of these have been shown
to be associated with increased risk of progression or death
from prostate cancer.
5.FutureResearch
Cell-cell signaling and the androgen receptor pathway
continue to be appropriate and promising targets for new
agents in men with prostate cancer. Currently being inves-
tigated are the risks and beneﬁts of the primary use or
adjuvant use of agents including somatostatin, or NF-κB
ligand (RANKL)receptor antagonists, RNF6-ubiquitiniation
inhibitors, aromatase inhibitors, or long-term antiandrogenProstate Cancer 5
Table 1: Summary of androgen deprivation indications.
ADT likely unwarranted ADT still warranted
Localized disease Advanced disease
(i) Preprostatectomy/postprostatectomy [30]( i ) P S A >50, PSADT<12 months [38]
(ii) Prior to EBXRT/Brachytherapy [33–36] (ii) Prior to EBXRT [43–47]
(iii) No primary treatment [37] (iii) Local obstructive symptoms and or metastatic disease [50]
(iv) Biochemical recurrence after therapy with PSADT>12
months [53] (iv) Lymph node involvement at prostatectomy [49]
(v) Biochemical recurrence after therapy with high risk of death
from prostate cancer [55–57],
Abbreviations. ADT: androgen deprivation therapy; EBXRT: external beam radiation; PSA: prostate-speciﬁc antigen; PSADT: prostate-speciﬁc antigen
doubling time.
monotherapy [32, 62–65]. The use of agents to reduce
production of dihydrotestosterone in the prevention of
prostate cancer is interesting, but so far does not appear
to improve the eﬃcacy of complete androgen blockade in
men with castration recurrent prostate cancer [66]. The
use of 1alpha, 25-dihydroxy vitamin D3 down regulates the
expression ofprostate-speciﬁc membrane antigen inprostate
cancer cells [67]. There is a possibility that these agents may
improve the eﬃcacy proﬁle of ADT and/or decrease its side
eﬀect proﬁle. LHRH antagonists have not been fully studied
in all of the scenarios mentioned above but are predicted
to have a similar eﬀect to LHRH agonists given with an
antiandrogen for the ﬁrst seven days as their suppression
of testosterone is similar [68, 69]. Additional promise lies
in pharmaceutical agents such as MDV 3100, an androgen
receptor antagonist that inhibits nuclear translocation and
DNAbinding, demonstrating activity in patients with CRPC
[70]. There is high anticipation regarding ongoing research
in prostate cancer drugs.
6.Summary
The use of ADT has long been recognized as a systemic
hormonal treatment for men with prostate cancer, and the
speciﬁc recommendations for its use continue to evolve.
There is increasing evidence over the last ﬁve years that
continuous long-term ADT causes multiple adverse side
eﬀects. Patients need to be evaluated for these risks and
should undergo monitoring for hyperlipidemia, coronary
artery disease, osteoporosis, and diabetes while castrate.
Further insight into the initiation of calcium and vitamin D
therapy are now recommended with the initiation of ADT.
Intravenous bisphosphonates should now be considered for
individuals with metastatic disease or osteoporosis. There is
evidence that suggests ADT is warranted in certain clinical
situations (see Table 1). However, these recommendations
are not ﬁrm guidelines and the risks and beneﬁts of ADT
must be weighed in any clinical situation. ADT should
not be considered primary therapy for men with low-
risk prostate cancer. ADT is discouraged in conjunction
with prostatectomy unless local lymph nodes are found
to be involved. ADT is generally not recommended in
patients with low-risk disease with adequate (70 to 79Gy)
conformal(145Gy),orbrachytherapyradiation.Inmenwith
a biochemical (PSA-only) recurrence after primary therapy,
the timing of the initiation of ADT should be considered
carefully. Those patients with high-stage (>2b), high-grade
tumors >7, with rapid PSA velocities before and/or after
treatment (total PSA>10ng/mL before treatment, doubling
time<12 monthsorabsolute increase of2ng/mL/year before
or after treatment), PSA nadir>0.2ng/mL, or overall high
total PSA (>50ng/mL) likely beneﬁt from early intervention
and possibly from involvement in a clinical trial. Additional
situations where ADT is strongly recommended are in a
neoadjuvant and setting for 4 to 6 months in men with
intermediate risk cancer undergoing radiation therapy or for
men with large prostates and low-risk cancer anticipating
brachytherapy; in an adjuvant setting for 2 to 3 years in men
with high-risk prostate cancer undergoing radiation therapy;
in men found to have positive nodes at prostatectomy;
in men with symptomatic (obstructing or painful) locally
advanced or metastatic disease. ADT may be considered
adjuvantly or neoadjuvantly in patients being treated with
cryotherapy. Studies regarding use of intermittent ADT,
cryotherapy, and androgen receptor pathway modulators are
ongoing but appear promising.
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